Nature Communications (Nov 2022)
Mucosal TLR2-activating protein-based vaccination induces potent pulmonary immunity and protection against SARS-CoV-2 in mice
- Anneliese S. Ashhurst,
- Matt D. Johansen,
- Joshua W. C. Maxwell,
- Skye Stockdale,
- Caroline L. Ashley,
- Anupriya Aggarwal,
- Rezwan Siddiquee,
- Stefan Miemczyk,
- Duc H. Nguyen,
- Joel P. Mackay,
- Claudio Counoupas,
- Scott N. Byrne,
- Stuart Turville,
- Megan Steain,
- James A. Triccas,
- Philip M. Hansbro,
- Richard J. Payne,
- Warwick J. Britton
Affiliations
- Anneliese S. Ashhurst
- School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney
- Matt D. Johansen
- Centre for Inflammation, Centenary Institute and Faculty of Science, School of Life Sciences, University of Technology
- Joshua W. C. Maxwell
- School of Chemistry, The University of Sydney
- Skye Stockdale
- School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney
- Caroline L. Ashley
- School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney
- Anupriya Aggarwal
- Kirby Institute
- Rezwan Siddiquee
- School of Life and Environmental Sciences, The University of Sydney
- Stefan Miemczyk
- Centre for Inflammation, Centenary Institute and Faculty of Science, School of Life Sciences, University of Technology
- Duc H. Nguyen
- Centre for Inflammation, Centenary Institute and Faculty of Science, School of Life Sciences, University of Technology
- Joel P. Mackay
- School of Life and Environmental Sciences, The University of Sydney
- Claudio Counoupas
- School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney
- Scott N. Byrne
- School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney
- Stuart Turville
- Kirby Institute
- Megan Steain
- School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney
- James A. Triccas
- School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney
- Philip M. Hansbro
- Centre for Inflammation, Centenary Institute and Faculty of Science, School of Life Sciences, University of Technology
- Richard J. Payne
- School of Chemistry, The University of Sydney
- Warwick J. Britton
- Tuberculosis Research Program Centenary Institute, The University of Sydney
- DOI
- https://doi.org/10.1038/s41467-022-34297-3
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 18
Abstract
Current vaccines against SARS-CoV-2 reduce mortality but are less effective in preventing infection. Here the authors show that intranasal vaccination with a subunit vaccine including an TLR2-stimulating adjuvant induces strong neutralising antibody and T-cell responses against SARS-CoV-2 in the lungs that protect against infection.
